Abstract
Introduction
Human Immunodeficiency Virus (HIV) is a lentivirus and a member of the retroviridae family that causes Acquired Immune Deficiency Syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life threatening opportunistic infections and cancer to thrive [1] . Two types of HIV have been characterized; HIV-1 and HIV-2 with the former being more virulent, more infective and is the cause of the majority of HIV infections globally while the latter has a lower infectivity and is largely confined to West Africa. HIV infects vital cells in the human system such as helper T cells (specifically CD 4 + T cells), macrophages and dendritic cells. HIV infection leads to low levels of CD 4 + T cells through three main mechanisms; Firstly, by a direct viral killing of infected cells, secondly by increased rate of apoptosis in infected cells and lastly by killing infected CD 4 + T cells by CD 8 cytotoxic lymphocytes that recognize infected cells. When CD 4 + T cell number decline below a critical level, cell mediated immunity is lost and the body becomes progressively more susceptible to opportunistic infections [2] .
Infections with HIV-1 are associated with progressive decrease of CD 4 + T cell count and an increase in viral load of HIV-infected patients. Most untreated people infected with HIV eventually develop AIDS. These individual mostly die from opportunistic infections or malignancies associated with the progressive failure of the immune system. Treatment with anti-retroviral therapy (ART) increases their life expectancies and this increase in life expectancy is being measured by the interaction between viral load and CD 4 + cell count in disease progression [3] .
A special relationship exists between viral load and CD 4 cell count. The interaction between the viral load and the CD 4 count can predict how fast or slow the final stage of AIDS is reached in an HIV-positive patient, while viral load is the actual number of viruses in the blood, an indication of how sick an HIV infected person is, it is used to measure the person's response to anti-retroviral treatment which is indicated in copies per mL. CD 4 cell count is an excellent indicator of how healthy the immune system is, which is indicated in cells per mm 3 . Viral load and CD 4 cell count vary together; a higher viral load will lead to a lower CD 4 count while a lower viral load will go hand in hand with a higher CD 4 cell count [4] .
This study focused on the effectiveness of Anti-retroviral Therapy (ART) in HIV patients' response to treatment which was indicated by the viral load as well as the CD 4 cell counts in blood samples of the infected patients.
II.
Materials And Methods
Study Area
The study was carried out in Our Lady of Apostles (OLA) Hospital located in Jos North Local Government Area of Plateau State, Nigeria. The State lies between latitude 80 0 24" north and longitude 80 0 32" and 100 0 38" east. Our Lady of Apostles Hospital Jos is one of the pioneer hospitals in the State Capital. It provides quality, preventive and curative health care services to the people of Plateau state and beyond.
Sample Size
A total number of 109 known HIV-1 infected patients, on Anti-Retroviral Therapy (ART) were used for the study. The minimum sample size of 109 was arrived at by using the standard (sample size) formula, n= zxzxpxq/dxd [5] , [6] and putting into consideration the HIV-1 prevalence in Plateau State of 7.7%. Where n=desired sample size, z=standard normal deviation at 1.96 which correspond to 95% confidence limit, p=proportion of population with HIV, and q=1-p. A semi-structured questionnaire was also used to collect some data as sex, age, lab number and drug combinations.
Ethical Clearance
Ethical clearance was obtained from the Ethical Committee of OLA Hospital and the individual participants. Also, for minors, clearance was obtained from the parent(s) or guardian. They were assured of full anonymity and all information obtained from them will be used confidentially and exclusively for the purpose of this study.
Equipment
The following equipment were used during the study; Cyflow, Partec GmbH, D-48161 Munster, Germany; Eppendorf Centrifuge 5218, Hamburg, Germany; NUAIRE Labgard, Class II, NU-425-400E, Biological Safety Cabinet; GeneAmp, PCR System 9700, Singapore; Molecular Device, Emax, China and other standard laboratory equipment.
Drug Administered to the Patients during the Study
The following ART drugs were administered to the patients during the study:
Sample Collection/Analysis
The infected patients were enrolled into the study after seeking their consent. Their blood samples were collected in EDTA containers for their baseline viral load and CD 4 cell estimations. Those with high viral load (≥400 copies/ml) and low CD 4 count (≤200cell/mm 3 ) were included in the study and commenced ART treatment. Their blood samples were again collected in EDTA containers after the commencement of the ART treatment at six (6) month intervals for two (2) years. The samples were investigated for CD 4 cell count and viral load; these were used as monitoring tools in studying the response of the patients to the anti-retroviral treatment.
Viral Load Assay
The AMPLICOR HIV-1 MONITOR test was with either of two specimen preparation procedures, the Standard procedure or the ultrasensitive procedure. In the standard specimen preparation procedure, HIV-1 RNA is isolated directly from plasma by lysis of virus particles with a chaotropic agent followed by precipitation of the RNA with alcohol. With the Ultra-Sensitive specimen preparation procedure, HIV-1 viral particles in plasma are concentrated by high speed centrifugation, followed by lysis of the virus particle with a chaotropic agent and precipitation of the HIV-1 RNA with alcohol. A known number of quantitation standard RNA molecules are introduced into each specimen with the lysis reagent. The HIV-1 Quantitation standard is carried through the specimen preparation, reverse transcription, amplification and detection steps and is used for the quantitation of HIV-1 RNA in the test specimen.
CD4 Cells Count
CD 4 -PE FLUORESCENCE was used in analyses on a partec flow cytometer with an excitation light source of 488 nm (blue or green solid state laser). To count CD 4 + T-cells, the test tube with 840 µl of the already prepared blood sample were transfered to partec flow cytometer and a count analysis was carried out. The blood preparation allows one count procedure on the same sample. Following the above procedure the dilution factor is 42. In the cyflow counter II and cyflow SL 3, this dilution factor is already set or can be directly set in the instrument software. Counting result will be displayed automatically as CD 4 + T-cell per µl whole blood.
Statistical Analysis
Data were presented as Frequency, Percentage, Chart and Mean ± SEM of the group and were analyzed using one-way analysis of variance (ANOVA) using SPSS 16.0 computer software package (SPSS Inc., Chicago, U.S.A) where appropriate. Differences at p<0.05 were considered significant.
III. Results
The age distribution of the volunteers is presented in Table 1 while Figure 1 shows their sex distribution. Table 2 and 3 reveals the viral load and CD4 response of the HIV patients respectively to ART at six months intervals while Table 4 shows their adherence and non-adherence during the study. 
IV. Discussion
Sampling of HIV-1 infected patients as revealed in Table 1 , shows that the age group with the highest HIV-1 prevalence rate was the 30 -39 years which had 38.53%. This age group is closely followed in prevalence by the 20 -29 years and 40 -49 years with 31.19% and 22.94% respectively. These groups are sexually active groups. It is however, a known fact that sexual intercourse is not the only means of transmission of the disease. The active age groups (20 -49 years) had a collective prevalence rate of 92.66% of the total study population.
Viral load response to ART after the initial commencement of treatment at the baseline time steadily improved as the course of treatment progressed throughout the study period of 24 months in all the studied age groups. A significant decrease (p<0.05) was recorded in these studied groups when compared with the baseline, with the 24 th month being significant when compared to other months amongst the 30 -39 years and 40 -49 year groups respectively (Table 2 ). This result is also a reflection of the adherence status of these age groups. Highest Percentage adherence of 84% was recorded in 40 -49 years (Table 4) .
A better result was observed in the CD 4 response of the patients. Significant increases (p<0.05) were recorded when compared with the baseline treatment before commencement of ART. All groups also showed a significant response when compared with other months (6th, 12th and 18th) except for 10 -19 and 50 -59 years (Table 3 ). These age groups had an excellent adherence status, which however might not have been a true reflection due to their sample size (Table 4) . Semi structured questionnaire revealed the adherence of the volunteers to the treatment regimen with 76.7% of them strictly adhering to the treatment instructions and periodicity. However, 23.3% of the test patients did not follow these instructions nor adhered to the periodicity of treatment schedule. Also 29.0% and 21.0% of those within the age range of 30 -39 years and 20 -29 years respectively failed to adhere to the given instructions (Table 4) .
V. Conclusion
This study clearly shows the effectiveness of ART therapy in the treatment of HIV-1 infected individuals, especially those infected with HIV-1 strain. Migueles and Connors, [3] reported that treatment with Anti-retroviral therapy (ART) increased the life expectancy of people infected with HIV, and this increase in life expectancy is measured by the interaction between viral load and CD 4 count in disease progression. This study also indicated that non-adherence to ART may present a drop in CD4 count and an increase in Viral load or a less significant response. These groups accounted for about 23.3% of the study population. Anti-retroviral Therapy (ART) presents a significant means of treatment and management regimen for HIV-1 infection while the use of viral load and CD 4 count values in the monitoring of the patients treatment and management is highly applauded and further advocated.
